Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell M2r4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkG0TWM2OD1yLkCwOlY6KM7:TR?= NIjkNXVUSU6JRWK=
MV-4-11 NIP4VINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEG1PFYh|ryP M1TLfHNCVkeHUh?=
NKM-1 M33GWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO3fnhiUUN3ME2wMlAyPjl7IN88US=> NX:xT4lZW0GQR1XS
ML-2 Ml\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjITWM2OD1yLkCxPVg{KM7:TR?= MlnJV2FPT0WU
BV-173 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnWdnVRUUN3ME2wMlAzOzF2IN88US=> M2e0XnNCVkeHUh?=
RS4-11 NWfXXI1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGToU2RKSzVyPUCuNFI2QDdizszN MUXTRW5ITVJ?
HL-60 M4jvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPOTWM2OD1yLkCyPVA5KM7:TR?= NG\WbWVUSU6JRWK=
KY821 NGTZXJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH3eHVKSzVyPUCuNFI6PzVizszN MVLTRW5ITVJ?
ECC10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEOyfplKSzVyPUCuNFM4QTJizszN MXHTRW5ITVJ?
NCI-H720 NYHLNYxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFr3fmNKSzVyPUCuNFQxOTFizszN MmGyV2FPT0WU
QIMR-WIL NYrERldbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrCWoRKSzVyPUCuNFQzQDdizszN M1z0[XNCVkeHUh?=
KG-1 M3POZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHuTWM2OD1yLkC0OFg3KM7:TR?= M1HaR3NCVkeHUh?=
TGW NEPsTGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIS1clNKSzVyPUCuNFQ3OzNizszN MmXqV2FPT0WU
ATN-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HkfGlEPTB;MD6wOFc{OyEQvF2= MVjTRW5ITVJ?
RH-18 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnqTWM2OD1yLkC2NFQ5KM7:TR?= M{DDOXNCVkeHUh?=
EW-18 M4HDUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr5eXhKSzVyPUCuNFY5PDFizszN NV3BWWxTW0GQR1XS
NB17 M1XxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHLTWM2OD1yLkC3NVI1KM7:TR?= NX[3[JZyW0GQR1XS
SK-NEP-1 M2\Kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LXZWlEPTB;MD6wO|IyOyEQvF2= MojCV2FPT0WU
P12-ICHIKAWA NFzneotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWG4XYx{UUN3ME2wMlA4Pzd6IN88US=> M{i0dnNCVkeHUh?=
KARPAS-45 MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnroTWM2OD1yLkC3PFE2KM7:TR?= NUHqeo5oW0GQR1XS
EW-3 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTBwMEiwOVMh|ryP MmS1V2FPT0WU
NB13 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwMEiyNFMh|ryP MXXTRW5ITVJ?
NCI-H209 NHvlcGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3uwNmlEPTB;MD6wPFcxPCEQvF2= NFXlWXJUSU6JRWK=
NCI-H1092 NYn4PWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMUCyO|Uh|ryP M1\r[3NCVkeHUh?=
NH-12 M1\FPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMUC3OFQh|ryP M{P5Z3NCVkeHUh?=
697 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMUC4N|kh|ryP NInlWYpUSU6JRWK=
KE-37 MlLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HFWWlEPTB;MD6xNVM4KM7:TR?= Mn;ZV2FPT0WU
MOLT-4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHYUnlyUUN3ME2wMlE2OTZ7IN88US=> MlrYV2FPT0WU
CHP-134 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS3[5BKSzVyPUCuNVY{ODZizszN NX3SUIF{W0GQR1XS
D-283MED MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwMUe2PFYh|ryP NEDMcYlUSU6JRWK=
LU-135 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwMUi1OVIh|ryP NFnScYVUSU6JRWK=
LU-134-A Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jCUWlEPTB;MD6xPFY4OSEQvF2= M{\hN3NCVkeHUh?=
EM-2 NFHp[JpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMUm5NVgh|ryP NGLGSIpUSU6JRWK=
LU-139 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHqcVRKSzVyPUCuNlA1QThizszN M33ZenNCVkeHUh?=
ALL-PO Mlv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMkG5PFgh|ryP NYLnTnM{W0GQR1XS
NB12 NHfJdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjXdGtKSzVyPUCuNlMyOTVizszN NUHrcFIxW0GQR1XS
KP-N-YN M17LRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\SOWlEPTB;MD6yN|U4OyEQvF2= NHuzZpVUSU6JRWK=
BEN NFnBe5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzQTWM2OD1yLkKzPVY5KM7:TR?= MVLTRW5ITVJ?
HCC1569 NUfhbGJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\MeYVZUUN3ME2wMlI2OTB4IN88US=> MmnBV2FPT0WU
HuO9 Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofBTWM2OD1yLkK2O|E2KM7:TR?= MXPTRW5ITVJ?
WM-115 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlZ|JKSzVyPUCuNlc4OzhizszN NHjzN4RUSU6JRWK=
CCRF-CEM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHr5d2FKSzVyPUCuN|M2OjlizszN MknGV2FPT0WU
IST-SL1 NHjoXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ToWmlEPTB;MD6zOVM1OyEQvF2= Mn7XV2FPT0WU
BE-13 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm2TWM2OD1yLkO2OFU6KM7:TR?= NGDJNlRUSU6JRWK=
COR-L88 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwM{[1OEDPxE1? M{j4NXNCVkeHUh?=
DOHH-2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwNEGwNlMh|ryP Mn7aV2FPT0WU
A704 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpWo5SUUN3ME2wMlQzPjdizszN NFnw[ZBUSU6JRWK=
KNS-81-FD MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorETWM2OD1yLkS0NFE4KM7:TR?= NEPvPJNUSU6JRWK=
RPMI-8226 NX\TeHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Xx[mlEPTB;MD60OVY2OiEQvF2= MXjTRW5ITVJ?
TGBC24TKB M4\NUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3n3NGlEPTB;MD60OVc4QCEQvF2= MkTEV2FPT0WU
NCI-H1304 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1PXpNUUN3ME2wMlQ3OTV5IN88US=> NX;2SWFwW0GQR1XS
MOLT-13 M33Vcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHaUGxKSzVyPUCuOFY3OTNizszN MXTTRW5ITVJ?
EW-22 NILG[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwNE[2O|Eh|ryP NEDMSVRUSU6JRWK=
MS-1 NGDU[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy3ZnM4UUN3ME2wMlQ3QTN|IN88US=> MkT3V2FPT0WU
RMG-I M1HTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S0O2lEPTB;MD60PVQ3PCEQvF2= MoLsV2FPT0WU
NTERA-S-cl-D1 NEPHcY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi2XYpbUUN3ME2wMlUxODF7IN88US=> MXTTRW5ITVJ?
NCI-H1048 NHvYNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwNUC5OVMh|ryP M3XrZnNCVkeHUh?=
SW1417 NED3TIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHIbmxKSzVyPUCuOVU1OzhizszN MYjTRW5ITVJ?
DB MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u0[GlEPTB;MD61O|A5KM7:TR?= MWnTRW5ITVJ?
MEG-01 NY\GRpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnrd2dqUUN3ME2wMlU5OzJizszN M1HkWXNCVkeHUh?=
EW-13 Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDxcY1KSzVyPUCuOVg{PDFizszN Ml;PV2FPT0WU
LAMA-84 Mn2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\wZmhKSzVyPUCuOVkzODdizszN MkTBV2FPT0WU
J-RT3-T3-5 M1TTfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvPTWM2OD1yLk[wPFA5KM7:TR?= M3XGPXNCVkeHUh?=
MOLT-16 NXfJfpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNkWyOlQh|ryP NF3KWXZUSU6JRWK=
DU-4475 NInNOHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37leGlEPTB;MD62OVQzPyEQvF2= MnLJV2FPT0WU
HAL-01 NID0THpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwN{K1OFkh|ryP MV;TRW5ITVJ?
RD NWm3N4xmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzFVmhLUUN3ME2wMlc2QDl7IN88US=> M3\idHNCVkeHUh?=
OAW-28 M37iN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTZTWM2OD1yLke4N|ch|ryP M3i4WHNCVkeHUh?=
HCC38 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor1TWM2OD1yLkiwNVkh|ryP MW\TRW5ITVJ?
NMC-G1 M1nuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLYTWM2OD1yLkixNVIyKM7:TR?= NFm1bYFUSU6JRWK=
EW-16 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\2TWM2OD1yLkixN|I5KM7:TR?= M{S5NnNCVkeHUh?=
DU-145 MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1WXNKSzVyPUCuPFk6OjNizszN Mn\FV2FPT0WU
HPAF-II MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO5PYNKSzVyPUCuPVI3OjhizszN M3TVWHNCVkeHUh?=
A427 NWPyb|ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTSXnlMUUN3ME2wMlk{ODJ{IN88US=> MkS5V2FPT0WU
PA-1 NELiXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;PWGlEPTB;MD65OVY1OiEQvF2= NGDD[4JUSU6JRWK=
OAW-42 M2DNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzRTWM2OD1yLkm2NVQ3KM7:TR?= MXrTRW5ITVJ?
L-428 NGqz[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvoemRmUUN3ME2xMlAyOjVizszN NWfHZZgxW0GQR1XS
COLO-824 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwMEG3NFgh|ryP MVjTRW5ITVJ?
P30-OHK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnrSm84UUN3ME2xMlA1Pjh6IN88US=> Ml:2V2FPT0WU
NCI-H2170 Ml7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKwV4JGUUN3ME2xMlA3OjNizszN NYLxfWRZW0GQR1XS
HCC2998 M2H2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPpUlFKUUN3ME2xMlA4OTN3IN88US=> MWfTRW5ITVJ?
NB14 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwMUO3OFgh|ryP M3;CSXNCVkeHUh?=
TGBC1TKB NHzId3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXhSGx2UUN3ME2xMlE1OTV{IN88US=> MUPTRW5ITVJ?
KP-N-YS NVvkTVJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LVb2lEPTB;MT6xOlI{PiEQvF2= NVqzOmx4W0GQR1XS
CAL-120 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ETWM2OD1zLkG2OFI6KM7:TR?= Ml\kV2FPT0WU
SBC-1 NUO3UZZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH4S2pKSzVyPUGuNVkxPTNizszN M1TGRXNCVkeHUh?=
C32 NX;qdWVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwMUmwPFgh|ryP MV7TRW5ITVJ?
HCC2157 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHGeW1YUUN3ME2xMlE6PDl2IN88US=> NH\6VndUSU6JRWK=
COLO-792 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwMkCwO|Eh|ryP M1fx[nNCVkeHUh?=
ES7 NWDpPXRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTFwMke5OVEh|ryP MlW2V2FPT0WU
HEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HFOGlEPTB;MT6zNVAzQSEQvF2= MUTTRW5ITVJ?
ES4 NUjOdYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwM{S5PVgh|ryP M2X0S3NCVkeHUh?=
NCI-SNU-1 MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLyWIZ7UUN3ME2xMlM3PTV3IN88US=> MlSwV2FPT0WU
MDA-MB-415 MonkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFu4eW1KSzVyPUGuN|g5PSEQvF2= MlG4V2FPT0WU
NCI-H2342 M1LjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnQbZRKSzVyPUGuOFAzPjlizszN Mn25V2FPT0WU
NB69 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTBNVdKSzVyPUGuOFYzPzFizszN M4\2d3NCVkeHUh?=
D-247MG NWPzVmxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHoTWM2OD1zLkWxNVIzKM7:TR?= MWTTRW5ITVJ?
SCC-4 NHfZXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17OXGlEPTB;MT61PVg5PyEQvF2= NITuSHVUSU6JRWK=
HuH-7 NFLRR5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYK1fo8zUUN3ME2xMlY4Ojl|IN88US=> MV7TRW5ITVJ?
A388 NVLn[FNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFwNki3NlQh|ryP M2HEcXNCVkeHUh?=
Calu-3 M4H0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rSV2lEPTB;MT63NFY6PyEQvF2= MlWxV2FPT0WU
NCI-H1648 NIfsTGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;6TVBKSzVyPUGuO|E1OThizszN NInRWWpUSU6JRWK=
NCI-H2052 M1XlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwN{KyNFEh|ryP MlTjV2FPT0WU
Ramos-2G6-4C10 MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUi2fVZsUUN3ME2xMlc{PjV4IN88US=> M2HneHNCVkeHUh?=
DEL NF7pdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHqeVNNUUN3ME2xMlc1Pjl{IN88US=> M4TvOHNCVkeHUh?=
SNU-423 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\YV4pKSzVyPUGuO|gyPTdizszN M1T3WXNCVkeHUh?=
COR-L23 M2ftZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17ZR2lEPTB;MT63PVg4PCEQvF2= M1jmTHNCVkeHUh?=
OMC-1 NFe2W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XlfWlEPTB;MT64OlAyPiEQvF2= NGPSbphUSU6JRWK=
EW-11 NVq5VmM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHBU4JIUUN3ME2xMlk2PjV5IN88US=> MkfIV2FPT0WU
HSC-3 NFTRbJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\SUnlKSzVyPUGuPVY{PjVizszN MWfTRW5ITVJ?
MLMA MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jNTWlEPTB;MT65OlY4PyEQvF2= M1KwZnNCVkeHUh?=
RCM-1 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHi1b49KSzVyPUKuNFA{QTlizszN MlnVV2FPT0WU
MFE-280 M{K5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjkZ5pVUUN3ME2yMlAzQDR6IN88US=> Mn3tV2FPT0WU
ES8 NFfScmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:zeVFqUUN3ME2yMlI2PDdzIN88US=> Mn7jV2FPT0WU
TE-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXpVHpKSzVyPUKuNlk1PzNizszN NEG0dnJUSU6JRWK=
HuO-3N1 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDuTWM2OD1{LkS4O|gh|ryP NFXYU3RUSU6JRWK=
MHH-NB-11 M{\zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJwNUGxOVgh|ryP NU\2dZl[W0GQR1XS
TGBC11TKB NYPTflJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXwTWM2OD1{LkW3OlgyKM7:TR?= M4fUb3NCVkeHUh?=
HOP-92 NVToWXVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i1RmlEPTB;Mj61PFc1OyEQvF2= MnPGV2FPT0WU
IGR-1 NUPJZ4NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[0WnVKSzVyPUKuOlIxOzVizszN NYftS3R1W0GQR1XS
GOTO M4iy[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJwNkWzO|ch|ryP NVntXno1W0GQR1XS
NCI-H1650 M1;iTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPGTWM2OD1{LkeyNlE2KM7:TR?= NXLMNnFmW0GQR1XS
NCI-H1581 M1fsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13FfmlEPTB;Mj63PVY5OSEQvF2= NFLuUnNUSU6JRWK=
NCI-H2405 NEnkXpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fMTGlEPTB;Mj64Nlc5OiEQvF2= M2Oy[HNCVkeHUh?=
U-118-MG NEjpUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnv2TWM2OD1{Lkm2OFkyKM7:TR?= MXTTRW5ITVJ?
DoTc2-4510 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTNwMEG0NVch|ryP M1XieHNCVkeHUh?=
NCI-H596 MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTlTWM2OD1|LkC0PVk4KM7:TR?= MVTTRW5ITVJ?
MPP-89 M{fVcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\sfmhKSzVyPUOuNFU3PjZizszN M2\afHNCVkeHUh?=
GCIY Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnpXYUyUUN3ME2zMlIxPDlzIN88US=> NWDwNFlQW0GQR1XS
SW626 NFXzV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\oTWM2OD1|LkK0OVQ{KM7:TR?= M3vvS3NCVkeHUh?=
OCI-AML2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPLTWM2OD1|LkOxNlczKM7:TR?= MmPsV2FPT0WU
NBsusSR MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jpWWlEPTB;Mz6zOFk{QCEQvF2= MY\TRW5ITVJ?
AN3-CA MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfFTWM2OD1|LkS0NlM5KM7:TR?= NHzleI9USU6JRWK=
EFM-19 NUDHR3drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHvTWM2OD1|LkS4N|M6KM7:TR?= Mm[xV2FPT0WU
RVH-421 M2rI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\0coNKSzVyPUOuOVY5PzdizszN NHzHfmFUSU6JRWK=
5637 M{ntb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;JVFZKSzVyPUOuOlEyODNizszN Mne4V2FPT0WU
PANC-08-13 NG\0SphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHaTWM2OD1|Lk[zOFczKM7:TR?= Mn\pV2FPT0WU
H9 NEPafYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTNwNkexOFQh|ryP NWDiTJNTW0GQR1XS
KARPAS-299 M3zxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf0U|AxUUN3ME2zMlY4OzZzIN88US=> MmDNV2FPT0WU
TE-5 NV7uSlVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\iTWM2OD1|LkewO|A6KM7:TR?= NUT5RlE4W0GQR1XS
NOS-1 MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHkTWM2OD1|Lke5PFM1KM7:TR?= MmSzV2FPT0WU
HH NELMeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVm4XXJFUUN3ME2zMlg{QDZ6IN88US=> MV;TRW5ITVJ?
769-P M1PGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;KTWM2OD1|Lki5OVEh|ryP Mk\zV2FPT0WU
CHP-212 M{XqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTNwOUK1OFkh|ryP M17XZ3NCVkeHUh?=
NCI-H82 NEewN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T1OGlEPTB;Mz65OVk{PiEQvF2= NELCe3RUSU6JRWK=
Mo-T MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TXcmlEPTB;ND6wOFMyOiEQvF2= NYj4TJJWW0GQR1XS
BB65-RCC MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTRwMESzPVkh|ryP MVrTRW5ITVJ?
SW1990 NXHDNZUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTRwMEW5NFgh|ryP NH\vNFZUSU6JRWK=
LK-2 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37hS2lEPTB;ND6xNVI6OyEQvF2= MlTCV2FPT0WU
ES5 MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fOPGlEPTB;ND6xN|k5PSEQvF2= MnPkV2FPT0WU
JVM-3 Mln6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDSb3JKSzVyPUSuNVgzOjJizszN NFfFVoNUSU6JRWK=
RPMI-7951 M4\5Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVex[ppIUUN3ME20MlIzPDF|IN88US=> M2XIU3NCVkeHUh?=
Calu-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW3TWM2OD12LkK3PFgyKM7:TR?= MWfTRW5ITVJ?
LC-2-ad NX\3O2xJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRwMkm1Olgh|ryP MkHzV2FPT0WU
SW954 MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnsXFZZUUN3ME20MlI6PjZizszN MYfTRW5ITVJ?
H-EMC-SS NIXvSnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTseZNKSzVyPUSuN|E5OzFizszN M1nHRnNCVkeHUh?=
ES3 NWXKW49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHHepd1UUN3ME20MlM2PDRzIN88US=> MYrTRW5ITVJ?
no-11 Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPLTWM2OD12LkO1OVU1KM7:TR?= NWXJWXkxW0GQR1XS
LAN-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nhVWlEPTB;ND60OVE5QSEQvF2= NGq5eZJUSU6JRWK=
FTC-133 NV\ndWY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPyTWM2OD12LkWzPVUh|ryP NH3CN|RUSU6JRWK=
8505C NXmzcmh1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HXVmlEPTB;ND61OFI{KM7:TR?= NETlU29USU6JRWK=
SW620 NHPUb5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLwOYtKSzVyPUSuOVcxPTdizszN MYXTRW5ITVJ?
BCPAP MmfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvoOlVqUUN3ME20MlY{PDhzIN88US=> MYHTRW5ITVJ?
SK-LU-1 NHjReHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[2XGlEPTB;ND62OlA5QSEQvF2= M1LsOXNCVkeHUh?=
NCI-H1623 Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HMNmlEPTB;ND63NFIzQCEQvF2= NXrtNFZyW0GQR1XS
C2BBe1 M2\RUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjZdXlKSzVyPUSuO|QxODhizszN M2e5SnNCVkeHUh?=
GP5d MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf6NoFKSzVyPUSuO|g{QDhizszN MnHGV2FPT0WU
NB6 NV\LfmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jiTGlEPTB;ND64OlIxPCEQvF2= NF\SWVhUSU6JRWK=
MDA-MB-157 MkLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jFVmlEPTB;ND64PFc3KM7:TR?= MW\TRW5ITVJ?
UMC-11 NWXjWlhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRwOEi5OlQh|ryP MkXDV2FPT0WU
HCC1419 NWX3bJRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXaVnRKSzVyPUSuPVAxPjNizszN MXLTRW5ITVJ?
NCI-H2029 NWHLUlh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\5[2lEPTB;ND65OFE5PSEQvF2= MXXTRW5ITVJ?
LXF-289 M1HxOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkK0TWM2OD13LkCzO|E6KM7:TR?= NIrQbVBUSU6JRWK=
KINGS-1 MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q5emlEPTB;NT6wO|c1PCEQvF2= MnfRV2FPT0WU
HD-MY-Z NFLO[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni3TWM2OD13LkKzPVY6KM7:TR?= MmTZV2FPT0WU
ESS-1 NHzLXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n5e2lEPTB;NT6yOVU6PyEQvF2= M3WzXXNCVkeHUh?=
GI-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH2TWM2OD13LkK3PVI3KM7:TR?= M{H6eXNCVkeHUh?=
RPMI-2650 NH6wRZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDs[GpXUUN3ME21MlM3OTZizszN MorlV2FPT0WU
IA-LM NXnMfld2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHYTWM2OD13LkO5PFcyKM7:TR?= NXm1OYNRW0GQR1XS
KP-4 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi4SXlTUUN3ME21MlQ3OzN2IN88US=> M2rDcnNCVkeHUh?=
G-402 MmTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\qNmlEPTB;NT61NVg3PSEQvF2= NH;BZnlUSU6JRWK=
OS-RC-2 M3rOe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTVwNUK2NFQh|ryP MnvjV2FPT0WU
NCI-H1155 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfRTWM2OD13LkW0PVU2KM7:TR?= NIi3TnBUSU6JRWK=
OE19 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL0fmZRUUN3ME21MlY5PjJ2IN88US=> NVjwdpB7W0GQR1XS
U-2-OS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFWwbmNKSzVyPUWuPFkxOTNizszN MULTRW5ITVJ?
SCC-15 NYG2RWhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{D1eWlEPTB;NT65N|Y3OiEQvF2= MlrBV2FPT0WU
NCI-H630 NXLPcJB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO4TWM2OD13Lkm5OFA1KM7:TR?= M2W5UnNCVkeHUh?=
PFSK-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofCTWM2OD14LkC1NlU6KM7:TR?= NW\5NoJyW0GQR1XS
NCI-H1770 NIrBZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XvOGlEPTB;Nj6yNFg4PCEQvF2= MVnTRW5ITVJ?
SK-MEL-3 M4PpSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17jcWlEPTB;Nj60NlkyPSEQvF2= NHz1OWZUSU6JRWK=
LB1047-RCC MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHHfFVKSzVyPU[uOFc3OjVizszN MVXTRW5ITVJ?
NCI-H446 MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvFflQ5UUN3ME22MlYzQTJ3IN88US=> MnrUV2FPT0WU
SW780 M17uZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfLb2J6UUN3ME22MlcxOTh3IN88US=> MoD0V2FPT0WU
NEC8 MlHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWfC[4JlUUN3ME22Mlc3PjNizszN MVjTRW5ITVJ?
NOMO-1 NFjPR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTZwN{ixNVEh|ryP M1LZWXNCVkeHUh?=
COLO-668 M1fqZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPqVVFKSzVyPU[uPFQ{QDdizszN NIrCdYZUSU6JRWK=
MC116 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XBW2lEPTB;Nj65N|g6PyEQvF2= NVXYXIU1W0GQR1XS
HCC1937 NX\qfZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;BTWM2OD14Lkm5NlUyKM7:TR?= M2C3WHNCVkeHUh?=
NCI-N87 NGrWToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTdwMUmyPVMh|ryP M{\yT3NCVkeHUh?=
COLO-320-HSR M2nnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmftTWM2OD15LkKyO|M5KM7:TR?= M1PFT3NCVkeHUh?=
HCC1806 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTdwMk[wOFQh|ryP MnHoV2FPT0WU
OVCAR-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTdwM{OwN|gh|ryP MWPTRW5ITVJ?
NUGC-3 NF\C[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzGWlNVUUN3ME23MlM6Pjl2IN88US=> NGnuZ41USU6JRWK=
SW1783 NW\iVpFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfOTWM2OD15LkSzNVc2KM7:TR?= NVTPd4VTW0GQR1XS
GCT MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;qWGlEPTB;Nz61OlkxPiEQvF2= MUPTRW5ITVJ?
NCI-H2126 NVf5WmRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrSXlR5UUN3ME23Mlc{PjJ3IN88US=> NYnV[IFOW0GQR1XS
MEL-HO Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWH4WW1qUUN3ME23Mlc4ODV2IN88US=> NWm4ZnRsW0GQR1XS
CAPAN-1 NVzPN|N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTdwN{ezOVch|ryP MnLpV2FPT0WU
SW756 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljwTWM2OD15Lke4N|M{KM7:TR?= MmTYV2FPT0WU
SKG-IIIa NHn6cIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTdwOEG4PVIh|ryP NFPFVpVUSU6JRWK=
HCE-T NULEboJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXNTWM2OD15Lki3O|g{KM7:TR?= MnTnV2FPT0WU
Ca-Ski MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL5O2VZUUN3ME23Mlk6Ozh|IN88US=> Mm\hV2FPT0WU
COLO-684 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXKTWM2OD16LkCxPFE5KM7:TR?= MYnTRW5ITVJ?
KYSE-70 NVrkT2NbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRThwMEe3Nlkh|ryP M2LrT3NCVkeHUh?=
TI-73 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PMWWlEPTB;OD6yOVg2OSEQvF2= NF[yPZNUSU6JRWK=
BT-20 MoXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRThwMk[wOVIh|ryP M1XieHNCVkeHUh?=
MHH-ES-1 M1fzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f4RWlEPTB;OD61NVg{PCEQvF2= NIHER|hUSU6JRWK=
TE-12 M2TKc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TDSmlEPTB;OD61PVk{OSEQvF2= MYfTRW5ITVJ?
YH-13 NHvxTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HlVWlEPTB;OD62NVAxQCEQvF2= NEfOdGNUSU6JRWK=
SF126 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTlTWM2OD16LkizPFY2KM7:TR?= M2qwTXNCVkeHUh?=
J82 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\sTWM2OD16LkmwNFM5KM7:TR?= NHu3NHVUSU6JRWK=
RCC10RGB MmHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnBPIZzUUN3ME24Mlk6PTZzIN88US=> MYfTRW5ITVJ?
SK-UT-1 NIDaPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTlwMES5OFUh|ryP M2Lte3NCVkeHUh?=
LB2241-RCC NEP2dFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\RbmlEPTB;OT6xPVE{PyEQvF2= MX\TRW5ITVJ?
LB996-RCC MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\sU2lEPTB;OT6xPVg6KM7:TR?= MV\TRW5ITVJ?
EPLC-272H MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoC0TWM2OD17LkO3OlU4KM7:TR?= MX\TRW5ITVJ?
CTV-1 NUjweFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTlwNU[1N|Ih|ryP NUW5NZFMW0GQR1XS
HSC-2 NU\DPXpUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XvO2lEPTB;OT61O|U2KM7:TR?= MYTTRW5ITVJ?
SK-MEL-28 MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTlwNkG4PVMh|ryP MnTVV2FPT0WU
MMAC-SF NX;VTlhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTlwNki3OUDPxE1? NVi1fGlHW0GQR1XS
CP50-MEL-B M{fvemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvITWM2OD17Lke1O|gzKM7:TR?= NES1[YRUSU6JRWK=
HT-1080 M3jhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;JTWM2OD17Lke3O|M6KM7:TR?= M{LQUHNCVkeHUh?=
HEC-1 NH7yXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDTWM2OD1zMD6zN|UzKM7:TR?= MYPTRW5ITVJ?
AGS NGT6SJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXuTWM2OD1zMD6zO|Qh|ryP MoLjV2FPT0WU
GAMG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDUTWM2OD1zMD61NVYzKM7:TR?= MYHTRW5ITVJ?
SW48 NUDlSZdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\zXpNKSzVyPUGwMlUyQDlizszN NFThRWJUSU6JRWK=
U031 NWDhSYt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2T6XGlEPTB;MUCuOVkxQCEQvF2= NFu3VIpUSU6JRWK=
OVCAR-5 NGrzPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFyLk[0Nlkh|ryP NIrDR4VUSU6JRWK=
SF295 M3PVOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUexe4lHUUN3ME2xNE43PzB2IN88US=> NUnydWwzW0GQR1XS
BHT-101 NIrOPVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\sTWM2OD1zMD63NVc4KM7:TR?= MlLBV2FPT0WU
VMRC-RCZ NX74VHN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\5Z2lEPTB;MUGuN|IxOSEQvF2= NGnBN2RUSU6JRWK=
ACHN MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqzU5VTUUN3ME2xNU41OjFzIN88US=> MXrTRW5ITVJ?
NCI-H526 M3vHN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFSwZYFKSzVyPUGxMlUxPDNizszN NYjQcZZlW0GQR1XS
MN-60 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfqTYpKSzVyPUGxMlU{QSEQvF2= NH6xZ3hUSU6JRWK=
NCI-H2291 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSxUXJtUUN3ME2xNU42PDZ4IN88US=> MoLjV2FPT0WU
SCC-25 M3vIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX31TFJQUUN3ME2xNU44PTV4IN88US=> M{X5fXNCVkeHUh?=
SK-MEL-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\MeI1CUUN3ME2xNU44PjN5IN88US=> MmrOV2FPT0WU
SN12C MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFzLkmzOVUh|ryP MWLTRW5ITVJ?
NCI-H69 MmLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXUVYtKSzVyPUGyMlQzOzRizszN MWXTRW5ITVJ?
ME-180 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTF{LkewOVQh|ryP MlzEV2FPT0WU
MC-IXC NIjIXW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:wXohKSzVyPUGyMlc2OThizszN NWDOelNKW0GQR1XS
NCI-H2347 M2TzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF{Lke2NVQh|ryP MWnTRW5ITVJ?
M059J NGPoUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjI[mllUUN3ME2xNk44PzJ5IN88US=> NYXYTYs5W0GQR1XS
A2058 NU\OUXNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF{Lki2PFEh|ryP M{n6UHNCVkeHUh?=
VA-ES-BJ M{TMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojiTWM2OD1zMj64O|g2KM7:TR?= MX3TRW5ITVJ?
Ca9-22 NGf4NZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7Gb5FKSzVyPUGyMlk1PTFizszN NGDMfo1USU6JRWK=
KNS-42 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDPU5B1UUN3ME2xNk46QTh2IN88US=> NWrMOHU{W0GQR1XS
LoVo MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPhTWM2OD1zMz6yN|E{KM7:TR?= Mn;rV2FPT0WU
AM-38 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfYZ25KSzVyPUGzMlI2PjZizszN M{fSU3NCVkeHUh?=
NB5 NEnLTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfv[mVKSzVyPUGzMlM4PTJizszN MnvRV2FPT0WU
L-363 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jNfmlEPTB;MUOuOFA{OyEQvF2= NFLZfoZUSU6JRWK=
SK-MEL-30 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLOfY57UUN3ME2xOE4xPjR3IN88US=> NHrBR3lUSU6JRWK=
NCI-H1563 NFS2d41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXewTXpIUUN3ME2xOE43ODN7IN88US=> NITkNlBUSU6JRWK=
NCI-H2228 NHrYdGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIWzc2JKSzVyPUG0MlYxPzdizszN NX64TWRMW0GQR1XS
MFM-223 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrKRnlKSzVyPUG1MlE5OTNizszN NE\0SGlUSU6JRWK=
LB831-BLC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj3TWM2OD1zNT6yO|Y4KM7:TR?= M2n5eXNCVkeHUh?=
SW872 NF7nPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\FTWM2OD1zNT6zNFg3KM7:TR?= MnrkV2FPT0WU
NCI-H522 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW2[HJSUUN3ME2xOU4{OzB4IN88US=> NILCWWpUSU6JRWK=
EW-1 M3HSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PqcGlEPTB;MUWuOVQ3OiEQvF2= NUnxOYVXW0GQR1XS
HN NXzyXpZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITzUVBKSzVyPUG1MlU6PDJizszN M1i2cXNCVkeHUh?=
SW837 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M334eWlEPTB;MUWuO|g1PyEQvF2= NUf4RYpJW0GQR1XS
SCC-9 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzrTWM2OD1zNT64NVE1KM7:TR?= MnTiV2FPT0WU
MKN7 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nkRWlEPTB;MUWuPVc{OiEQvF2= MlnvV2FPT0WU
KYSE-410 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DxSGlEPTB;MU[uOVkyKM7:TR?= NY\HT|NCW0GQR1XS
SK-N-DZ NF7l[3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF4Lk[xNVYh|ryP M3PWSXNCVkeHUh?=
COR-L105 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WwdWlEPTB;MU[uOlUzQCEQvF2= MVTTRW5ITVJ?
LB2518-MEL NHXNc49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTF4LkizPFkh|ryP NWHEWHAyW0GQR1XS
OVCAR-4 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjvc4lQUUN3ME2xOk45QDZ{IN88US=> MYfTRW5ITVJ?
TK10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDOS3pKSzVyPUG2Mlk1PzNizszN NGS1dmxUSU6JRWK=
KNS-62 M{PqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF4Lkm3O|ch|ryP MYXTRW5ITVJ?
RPMI-8866 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF5LkG3N|Ih|ryP NWnL[IVMW0GQR1XS
HuP-T4 NH3Dd|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF5LkK0PVUh|ryP MlzMV2FPT0WU
CGTH-W-1 NWjwR3VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XFN2lEPTB;MUeuOVIyQSEQvF2= NHn1VVlUSU6JRWK=
T-24 NIf5N4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\q[FRKSzVyPUG3MlU{PDdizszN MVrTRW5ITVJ?
HT-3 MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTF5LkW5NVQh|ryP M2T3[nNCVkeHUh?=
KS-1 MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF5Lk[3N{DPxE1? NVTDe3RwW0GQR1XS
NCI-H1792 NVi5[IxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLWeIdKSzVyPUG3Mlc6QCEQvF2= M{PtbXNCVkeHUh?=
ABC-1 NHHVUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF5LkixOFEh|ryP MUHTRW5ITVJ?
BPH-1 NHjEVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF6LkG2PFUh|ryP M13jXHNCVkeHUh?=
A431 M4PLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3hW|JKSzVyPUG4MlQyOjdizszN M4LTc3NCVkeHUh?=
T98G M1TGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF6LkWxOVch|ryP NHryVXZUSU6JRWK=
BHY NXvJNYViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPhNIhKSzVyPUG4Mlg3QSEQvF2= MmXtV2FPT0WU
Capan-2 M2fJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXq3dnA5UUN3ME2xPE46ODd6IN88US=> MYjTRW5ITVJ?
MDA-MB-175-VII M1f4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHrZZVKSzVyPUG4MlkzODlizszN M4C0[XNCVkeHUh?=
CAL-27 NHHtUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF7LkC0PFch|ryP NV32eVZDW0GQR1XS
AsPC-1 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Ob5ZuUUN3ME2xPU45PjV5IN88US=> NFPFd4VUSU6JRWK=
KU812 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPWTWM2OD1zOT65OVc{KM7:TR?= MoDDV2FPT0WU
NCI-H441 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PiS2lEPTB;MkCuNFAyKM7:TR?= MkjNV2FPT0WU
Mewo NF\USIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorFTWM2OD1{MD6xNlg5KM7:TR?= MnG3V2FPT0WU
SK-MEL-24 M4XD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDjTWM2OD1{MD6xOFc4KM7:TR?= Mo\FV2FPT0WU
NCI-H727 NUXYfo1LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TmcGlEPTB;MkCuNlcxPCEQvF2= MVrTRW5ITVJ?
EKVX MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe1cpRKSzVyPUKwMlYxPiEQvF2= MXLTRW5ITVJ?
RT-112 M3vxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnETZhKSzVyPUKwMlYyOjJizszN NIL5dlBUSU6JRWK=
CAMA-1 M{nhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTJyLkm4NFMh|ryP NULw[m1pW0GQR1XS
SW900 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1L0U2lEPTB;MkGuNFE1QSEQvF2= MWnTRW5ITVJ?
NCI-H23 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;TVlV6UUN3ME2yNU4yOjd5IN88US=> M3uyO3NCVkeHUh?=
SK-PN-DW Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jjfGlEPTB;MkGuNVY1QSEQvF2= NUD4[XJJW0GQR1XS
BB30-HNC M{LBNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnxU2FoUUN3ME2yNU4zPzR3IN88US=> NIPaUlBUSU6JRWK=
VM-CUB-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXJUHE3UUN3ME2yNU4{PTN4IN88US=> MnnDV2FPT0WU
IST-MEL1 NVnKT4t1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnJOFI2UUN3ME2yNU4{Pjl{IN88US=> NVHZW2VsW0GQR1XS
CTB-1 M2LNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ITWM2OD1{MT60O|U2KM7:TR?= M1HTO3NCVkeHUh?=
LCLC-103H NEHGV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFi2ZVhKSzVyPUKyMlE2QDJizszN NW\WeZo1W0GQR1XS
PANC-03-27 NYjxZm1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXEXZhKSzVyPUKyMlUyPjlizszN M{\sbHNCVkeHUh?=
HTC-C3 MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ{LkW1OVUh|ryP MX;TRW5ITVJ?
TE-8 MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\TXYVkUUN3ME2yN{4zPTZ3IN88US=> MlPMV2FPT0WU
NCI-H292 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJ3LkO1N|Yh|ryP M3TJ[XNCVkeHUh?=
COLO-680N NUTS[pdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHKRXRKSzVyPUK1MlY{OjlizszN NV;LU4t7W0GQR1XS
KYSE-520 M4HIbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfvcnBKSzVyPUK1MlY1PCEQvF2= NWPoeXlVW0GQR1XS
NB10 NWnrSWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X5V2lEPTB;Mk[uN|EyPyEQvF2= MWHTRW5ITVJ?
NCI-H661 M3nscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fqPGlEPTB;Mk[uOFcyOyEQvF2= MnzvV2FPT0WU
GMS-10 NFHqRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTlR5FzUUN3ME2yOk45PjN6IN88US=> NF7UUVVUSU6JRWK=
NCI-H2122 NGrncYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M324bGlEPTB;Mk[uPVk6QCEQvF2= Mo\2V2FPT0WU
OVCAR-8 M2PMc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzBN4xKSzVyPUK3MlA3OzhizszN MlXGV2FPT0WU
DJM-1 NYfoXVVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jmfGlEPTB;MkeuNVQ2PCEQvF2= MXPTRW5ITVJ?
UACC-893 NHfJNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJ5Lkm4O|gh|ryP MlrBV2FPT0WU
C8166 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHYeXg{UUN3ME2yPE43QTN6IN88US=> M1;5NHNCVkeHUh?=
NCI-H1693 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXoSJpLUUN3ME2yPE43QTd3IN88US=> NFjsOVBUSU6JRWK=
TYK-nu Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNyLkCzOFUh|ryP MmqyV2FPT0WU
SW1710 M{DFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG0Uo5WUUN3ME2zNE4yOjZizszN NIO3PFFUSU6JRWK=
A375 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNyLkOyOFMh|ryP NGjDWWpUSU6JRWK=
HMV-II M3rZb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTNzLkO1PVIh|ryP NGiwfXJUSU6JRWK=
NCI-H2087 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjTTWM2OD1|MT62N|UzKM7:TR?= NIS4V4FUSU6JRWK=
CAL-54 NIjyXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLDN4RbUUN3ME2zNU44OjRzIN88US=> M3jNdHNCVkeHUh?=
HCC70 NYn0[olpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrvTWM2OD1|Mj6xN|g4KM7:TR?= NXL5[YZQW0GQR1XS
ES1 NWSybnpuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HGPWlEPTB;M{KuN|A3OiEQvF2= NIXmdZRUSU6JRWK=
NCI-H1355 NFrLcVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHOTWM2OD1|Mz6yNFQh|ryP MkDnV2FPT0WU
CFPAC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[3NGlEPTB;M{OuNlM{OiEQvF2= NGXYU5JUSU6JRWK=
MKN28 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\5XWlEPTB;M{OuN|gxQSEQvF2= M{K3bnNCVkeHUh?=
HDLM-2 NXrw[mFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfVTWM2OD1|Mz62PVMyKM7:TR?= MXrTRW5ITVJ?
PANC-10-05 NHiweYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnyVWNKSzVyPUO0MlExOTRizszN MknHV2FPT0WU
SAS M{jO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYSwfY9nUUN3ME2zOE41PTZ3IN88US=> MkHiV2FPT0WU
HCC1395 NYHIWYtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTN2LkexPFYh|ryP NGPDWmpUSU6JRWK=
8305C M{XVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDUXZMyUUN3ME2zOU45PDF3IN88US=> NFjHW4tUSU6JRWK=
KM12 NYfQOmt2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTN4Lke1OFch|ryP MWHTRW5ITVJ?
SW1116 NFzvSWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN5LkW5PVIh|ryP MXHTRW5ITVJ?
SK-MEL-1 Ml\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\TfWlEPTB;M{iuN|M5QSEQvF2= NX3UfmVVW0GQR1XS
HCC2218 NHHjeZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2W1cWlEPTB;M{iuOlUyQSEQvF2= M3m0XXNCVkeHUh?=
T84 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DpT2lEPTB;M{iuO|QxQSEQvF2= M1fXVHNCVkeHUh?=
ETK-1 MkDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfTTWM2OD1|OT6wNlIh|ryP M1:zTnNCVkeHUh?=
COLO-800 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjaTWM2OD1|OT6zPFY5KM7:TR?= M4f5SXNCVkeHUh?=
CAL-12T NFnVelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4izcWlEPTB;M{muOVI5OSEQvF2= M4DsdXNCVkeHUh?=
ACN NFnvVGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjz[VlKSzVyPUSwMlQ6OTFizszN M3Wz[XNCVkeHUh?=
SJSA-1 NUTKeplVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlSyTWM2OD12MT6xOVk3KM7:TR?= MXXTRW5ITVJ?
PSN1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuTWM2OD12MT6xO|Q6KM7:TR?= MmfmV2FPT0WU
D-566MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnITGJMUUN3ME20NU4zODh4IN88US=> NXLEbI1JW0GQR1XS
EGI-1 NV\1dJd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX73cIdwUUN3ME20Nk41OjhizszN MVvTRW5ITVJ?
A204 NEjZOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PJOmlEPTB;NEKuOlM5QCEQvF2= NYfpSVZIW0GQR1XS
Saos-2 M4P6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLzTWM2OD12Mj64N|Y6KM7:TR?= M3HmeXNCVkeHUh?=
SNU-C2B NG\QW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPoTWM2OD12Mz62PFc5KM7:TR?= MXvTRW5ITVJ?
HLE NFXrUWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\YTWM2OD12ND6wPFU3KM7:TR?= Ml3FV2FPT0WU
SW1463 NF;ibllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq3NYRtUUN3ME20OE46QTdzIN88US=> NUjUWZd[W0GQR1XS
DSH1 MkP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;EXGlEPTB;NEWuNFA{OyEQvF2= MkLjV2FPT0WU
MCF7 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTR3LkWwOVEh|ryP NFTFbHpUSU6JRWK=
K5 M2HHUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17JNmlEPTB;NEWuPVQxPSEQvF2= MmLxV2FPT0WU
NCI-H358 NWHTOZRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHHWIRKSzVyPUS3MlIyPSEQvF2= M1rndHNCVkeHUh?=
NCI-H2030 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TvUmlEPTB;NEeuNlM4PCEQvF2= NHzEdIxUSU6JRWK=
SW948 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXBZo9DUUN3ME20O{41PjRizszN MlXXV2FPT0WU
BALL-1 NGr0bplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTR5Lk[xOlgh|ryP M3fVe3NCVkeHUh?=
TE-9 NUi3NI5ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f2W2lEPTB;NEeuPVU5OSEQvF2= M{\rUHNCVkeHUh?=
SK-N-FI NUTWV|JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfkRpNDUUN3ME20PE4xOzV6IN88US=> NV\SWpBjW0GQR1XS
KALS-1 NYjkdXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jwTWlEPTB;NEiuNVI5QSEQvF2= Mof1V2FPT0WU
HO-1-N-1 NH3MPIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPEZ2k{UUN3ME20PE44PDR3IN88US=> Ml;LV2FPT0WU
NCI-H2452 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTR7LkGxOVIh|ryP Mn[0V2FPT0WU
OC-314 MoD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTR7Lk[4N|Qh|ryP M33PUnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID